Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

September 1, 2027

Conditions
Resectable Clear Cell Carcinoma of the Kidney
Interventions
DRUG

cardonilizumab combined with renvastinib

Preoperative: Cardenilimab: 10 mg/kg qd intravenously, one cycle every 21 days, administered on the first day of each cycle, a total of 4 cycles. Lenvatinib: Weight \<60kg, 8mg, once a day, orally, for 4 cycles Weight \>60kg, 12mg, once a day, orally, for a total of 4 cycles Surgery: The patient is receiving 4 cycles of cardenilimab + Standard radical nephrectomy was performed within 30-40 days after the end of lenvatinib treatment. Postoperative: Cardenilimab: 10 mg/kg qd intravenously, 1 cycle every 21 days, administered on the 1st day of each cycle, a total of 8 cycles Lenvatinib: body weight \<60 kg, 8 mg, once a day, orally , a total of 8 cycles, weight \> 60kg, 12mg, once a day, orally, a total of 8 cycles.

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT06574412 - Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. | Biotech Hunter | Biotech Hunter